**Supplementary information S2 (table) | Ang-1, Ang-2 and sTie2 as circulating biomarkers**

<table>
<thead>
<tr>
<th>Process / Disease</th>
<th>Finding</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANGIOPOIETIN-2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute lung injury and adult respiratory distress syndrome (ARDS)</td>
<td>Increased Ang-2 levels</td>
<td>1</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia</td>
<td>Increased Ang-2 levels</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Decreased Ang-2 levels after Dexamethasone intervention</td>
<td></td>
</tr>
<tr>
<td>Esophageal squamous cell cancer</td>
<td>Increased Ang-2 levels</td>
<td>3</td>
</tr>
<tr>
<td>Hepatocellular carcinoma (HCC)</td>
<td>Increased Ang-2 levels; lower survival-rate</td>
<td>4</td>
</tr>
<tr>
<td>HCC and liver cirrhosis</td>
<td>Increased Ang-2 levels</td>
<td>5</td>
</tr>
<tr>
<td>Hypertension related myocardial infarction (MI)</td>
<td>Increased Ang-2 levels</td>
<td>6</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Increased Ang-2 levels</td>
<td>7</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Increased Ang-2 levels</td>
<td>8</td>
</tr>
<tr>
<td>Placental insufficiency</td>
<td>Decreased Ang-2 levels</td>
<td>9</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>Increased Ang-2 levels</td>
<td>10</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>Increased Ang-2 levels</td>
<td>11</td>
</tr>
<tr>
<td>Proliferative diabetic retinopathy</td>
<td>Increased Ang-2 levels</td>
<td>12</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Increased Ang-2 levels</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Induction of inflammatory mediators</td>
<td></td>
</tr>
<tr>
<td>Sepsis</td>
<td>Increased Ang-2 levels</td>
<td>14, 15</td>
</tr>
<tr>
<td>Trauma</td>
<td>Increased Ang-2 levels</td>
<td>16</td>
</tr>
<tr>
<td><strong>ANGIOPOIETIN-1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early arthritis</td>
<td>Increased Ang-1 levels</td>
<td>17</td>
</tr>
<tr>
<td><strong>ANGIOPOIETIN-1 and ANGIOPOIETIN -2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Similar Ang levels in aortic root, coronary ostium, coronary sinus,</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>and femoral vein</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase of Ang-1/-2 after intervention</td>
<td></td>
</tr>
<tr>
<td>Colorectal resection</td>
<td>Time-dependent changes in Ang-1/-2 levels</td>
<td>19</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Increased Ang-2 levels</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Normal Ang-1 levels</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>Increased Ang-1 levels</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Decreased Ang-2 levels after intervention</td>
<td></td>
</tr>
<tr>
<td>M. Waldenström (Non-Hodgkin-Lymphoma)</td>
<td>Decreased ratio of Ang-1 and Ang-2</td>
<td>22</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>Normalization Ang-1/Ang-2 ratio reflects Bortezomib-responsiveness</td>
<td>23</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Decrease of Ang-1/-2 levels after prostatectomy</td>
<td>24</td>
</tr>
</tbody>
</table>
## Process / Disease | Finding | Reference
---|---|---
**ANGIOPOIETIN -1 and ANGIOPOIETIN -2**
Septic shock | Decreased Ang-1 levels; increased Ang-2 levels | 25

**ANGIOPOIETIN -1 and ANGIOPOIETIN -2 and soluble TIE2 (sTIE2)**
Acute coronary syndrome | Phase-dependent increase/decrease of Ang-1/-2 and sTie2 levels | 26
Breast and prostate cancer | Correlation dependent levels of Ang-1/-2 and sTie2 | 27
Congestive heart failure | Increased Ang-2 and sTie2 levels; normal Ang-1 levels | 28
Coronary artery disease | Increased sTie2 levels in patients with well developed collaterals; Positive correlation between coronary Ang-2 and sTie2 levels | 29
Hypertension | Increased Ang-1/-2 and sTie2 levels | 30
Pregnancy induced hypertension and preeclampsia | Study group-dependent increase/decrease of Ang-1/-2 and sTie2 levels | 31
Sickle cell disease | Increased Ang-1/-2 and sTie2 levels | 32
Thyroid cancer | Decreased Ang-1 levels; Decreased Ang-2 levels | 33

**ANGIOPOIETIN -2 and soluble TIE2 (sTIE2)**
Acute myeloid leukemia (AML) | Increased Ang-2/sTie2 levels lower 3 year survival-rate | 34
Diabetic retinopathy | Increased Ang-2 levels; decreased sTie2 levels | 35
Hematological malignancies | Increased Ang-2/sTie2 levels; decreased Ang-2/sTie2 levels after therapeutic intervention | 36
Inflammatory bowel disease | Increased Ang-2/sTie2 levels | 37
Ovarian stimulation/early gestation | Increased Ang-2 levels; Normal sTie2 levels | 38

**soluble TIE2 (sTIE2)**
Acute myocardial infarction | Increased sTie2 levels | 39
Acute myocardial infarction | Increased sTie2 levels | 40
Cerebral ischemia | Increased sTie2 levels | 41
Colorectal cancer | Increased sTie2 levels | 42
Colorectal cancer | Increased sTie2 levels | 43
Corneal neovascularization | Increased sTie2 levels | 44
Coronary artery disease | Increased sTie2 levels | 45
Dural arteriovenous malformation | Increased sTie2 levels; Decreased sTie2 levels after intervention | 46
### References


